title: Down syndrome serum marker screening: decision criteria and implicit values.
abstract: Maternal serum markers assess the individual risk of giving birth to a fetus with Down syndrome. Because this information is a probability, and because of the infinite number of cut-off risks that can be adopted, a decision criterion is needed to define a population screening program. While a decision criterion for cut-off risks may refer to arbitrations between risks, another criterion must be considered. This criterion focuses on a societal perspective by comparing the costs of the program to the expected benefits. We will first discuss the questions that are raised when assessing, in terms of cost-effectiveness, the consequences of having adopted the policy maker's preferences for prenatal diagnosis referral. Subsequently, we will discuss the implicit values attributed to the outcomes of the program when the societal point of view is reduced to societal profitability. This is accomplished by means of a cost-benefit analysis using the 'avoided costs' approach. The consequences of screening with 'double' and 'triple' tests were assessed using a database made of 10,108 observations, including 63 Down syndrome cases. For a cut-off risk of 1:250 (resulting in a 7% amniocentesis referral rate, regardless of the technique), conclusions in terms of decision making differ according to the effectiveness indicator. Although a criterion based on resource allocation would promote the triple test, cost-benefit analysis points out the impact on results of factors such as the amniocentesis related fetal losses or the introduction of equity principles.
authors.affiliation: Center of Health Economics Research, INSERM Unit 357-CNRS ERS 387, Hôpital de Bicêtre, Cedex, France. seror@kb.inserm.fr
authors.forename: V
authors.initials: V
authors.lastname: Seror
authors.forename: N
authors.initials: N
authors.lastname: Costet
mesh_terms: D000328:Adult; D000649:Amniocentesis / Q000009:adverse effects / Q000191:economics / Q000706:statistics & numerical data; D015415:Biomarkers; D003362:Cost-Benefit Analysis; D003657:Decision Making; D003955:Diagnostic Tests, Routine / Q000191:economics* / Q000592:standards; D004314:Down Syndrome / Q000175:diagnosis*; D005260:Female; D005602:France; D015276:Health Care Rationing / Q000191:economics*; D006291:Health Policy; D006801:Humans; D008431:Maternal-Fetal Exchange; D017063:Outcome Assessment, Health Care; D011247:Pregnancy; D011296:Prenatal Diagnosis / Q000191:economics* / Q000592:standards; D018570:Risk Assessment; D012945:Social Values